COVID-19 vaccines have been given emergency use authorization in numerous countries worldwide. However, most COVID-19 vaccination studies excluded individuals with active cancer; thus, evidence on the vaccines' safety, tolerability, and effectiveness in cancer patients are currently limited. Given the threat posed by the COVID-19 pandemic, decisions about the use of COVID-19 vaccinations in patients enrolled in clinical trials for testing the effectiveness of novel anticancer medicines must be made on priority. This article summarizes the guidance for COVID-19 vaccination recommendations for patients enrolled in cancer clinical trials.
Patient prioritization COVID-19 vaccinations should be made available to all cancer patients, even those enrolled in research trials. Therefore, vaccination should be the standard of care for patients participating in cancer therapy trials. Eligible…
